Australian-based biotech firm Actinogen Medical has begun patient enrolment and dosing in the Phase II XanADu clinical trial of Xanamem for the treatment of Alzheimer’s disease.

Developed in collaboration with Edinburgh University in Scotland, Xanamem is designed to block the excess production of cortisol in the brain.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

The initiation of patient enrolment follows the approval from the Australian Therapeutic Goods Administration (TGA), the US Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA).

The double-blind, randomised, placebo-controlled Phase II trial will evaluate the safety, tolerability and efficacy of Xanamem over 12 weeks in patients with mild dementia.

"It is significant that the first XanADu patient worldwide has been enrolled in Australia and we can all be justifiably proud that Australia is leading the way in developing this promising new treatment for Alzheimer’s disease."

Actinogen Medical chief executive officer Dr Bill Ketelbey said: “It is significant that the first XanADu patient worldwide has been enrolled in Australia and we can all be justifiably proud that Australia is leading the way in developing this promising new treatment for Alzheimer’s disease.

“Given the growing number of people with Alzheimer’s and the critical importance of finding effective new drugs to treat this disease, our hope is that the development of Xanamem will make a real difference to Alzheimer’s patients, and their carers and families worldwide.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

With the first patient recruited at the Central Coast Neurosciences Research site in New South Wales, Australia, the trial is expected to enrol a total of 174 patients across 20 clinical sites in the US, the UK and Australia.

The final patient is expected to be enrolled into the trial by the fourth quarter of next year and the top line results are estimated to be reported in the first quarter of 2019.